Chemotherapy-induced Peripheral Neuropathy (CIPN)
Conditions
Keywords
paclitaxel, neuropathy, hypothermia, cryocompression
Brief summary
The project is designed to study the use of localized hypothermia alone, or with compression to the limbs during chemotherapy infusion for the prevention of chemotherapy induced peripheral neuropathy (CIPN). As a pilot study, safety, tolerability and early clinical activity will be studied. The study will be conducted on healthy volunteers and cancer patients receiving taxane chemotherapy.
Detailed description
Localized limb hypothermia during chemotherapeutic infusion may prevent a common side effect of chemotherapy: chemotherapy-induced peripheral neuropathy (CIPN). There are no reliable methods for the prevention or the treatment of CIPN. On the basis of the dose-related pathophysiology of CIPN, the investigators hypothesize that reducing the delivery of the toxic chemotherapeutic agents to the peripheral nerves by reducing blood flow through hypothermia may reduce the occurrence of CIPN. The proposed potential treatment method would aim to reduce the development of CIPN. This project comprises of a healthy subject trial to investigate the best tolerated temperature which will be used in cancer subject trial to investigate the safety and tolerability of hypothermia or cryocompression (hypothermia with pressure) in the prevention of CIPN in cancer subjects undergoing taxane-based chemotherapy.
Interventions
DEVICEHypothermia
Healthy subjects will undergo 3 hours of hypothermia at various temperature levels.Cancer subjects will undergo 4 hours of hypothermia during every cycle of chemotherapy.
DEVICECryocompression
Healthy subjects will undergo 3 hours of cryocompression. Cancer subjects will undergo a minimum duration of 2 hours and a maximum duration of up to 4 hours of cryocompression during every cycle of chemotherapy.
Sponsors
National University Hospital, Singapore
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
PREVENTION
Masking
NONE
Intervention model description
The first part of this study is in healthy subjects, followed by breast cancer patients receiving paclitaxel to study the effect of limb hypothermia in the prevention of chemotherapy-induced neuropathy. The second part of this study is to study the effect of cryocompression in the prevention of chemotherapy-induced neuropathy.
Eligibility
Sex/Gender
ALL
Age
21 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
The inclusion criterion for the healthy subjects * Age 21-80 years * Signed informed consent from patient * No history of neuropathy * ECOG 0 * No history of hospitalization in the past 6 months The inclusion criteria for the cancer patients undergoing taxane-based chemotherapy * Age 21- 80 years. * Signed informed consent from patient or legal representative. * Scheduled to receive taxane-based chemotherapy The
Exclusion criteria
for both healthy subjects and cancer patients * Open skin wound or ulcers of the limbs * A score of more than 5 in the Total Neuropathy Score (TNS) at baseline (Not applicable for healthy subjects) * History of Raynaud's phenomenon, peripheral vascular disease, or poorly controlled diabetes
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of healthy subjects with treatment-related intolerance as assessed by CTCAE v4.0 and tolerability scales undergoing limb hypothermia or cryocompression | From the start of assessment until study completion, an average of 3 years |
| Number of cancer patients with treatment-related intolerance as assessed by CTCAE v4.0 and tolerability scales undergoing limb hypothermia or cryocompression | From the start of assessment until study completion, an average of 3 years |
Outcome results
None listed